Chemokine Therapeutics receives U.S. Patent for novel cancer drug in clinical development
17-Jun-2005 -
Chemokine Therapeutics Corp. announced that it has been granted U.S. Patent No. 6,875,738
relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells. ...
angiogenesis
chemokines
chemotherapy
+8